What Is EW Fair Value?
Edwards Lifesciences (EW) fair value estimate using multiple valuation models, updated daily.
As of July 16, 2026, Edwards Lifesciences (EW) has a composite fair value estimate of $50.42 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $87.27, suggesting the stock is overvalued by 42.2%.
Data as of July 16, 2026 (today)
Composite Fair Value
Overvalued3 of 4 models$50.42
vs. current price of $87.27(-42.2%)
How Is EW Fair Value Calculated?
Four independent models estimate what EW is worth. Each uses different inputs and assumptions. The composite blends them by weight.
EW Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
41% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$56.06
-35.8%Overvalued
Inputs used
DDM (Dividend Discount Model)
0% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
N/A
This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.
EW Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
29% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$34.80
-60.1%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
29% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$44.30
-49.2%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $87.27 is 35.8% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $1.04B | $948.4M |
| Year 2 | $1.19B | $997.1M |
| Year 3 | $1.36B | $1.05B |
| Year 4 | $1.56B | $1.10B |
| Year 5 | $1.79B | $1.16B |
| Year 6 | $2.06B | $1.22B |
| Year 7 | $2.36B | $1.28B |
| Year 8 | $2.71B | $1.35B |
| Year 9 | $3.11B | $1.42B |
| Year 10 | $3.56B | $1.49B |
| Terminal Value | $55.11B | $23.00B |
What Are EW's Key Financial Metrics?
Earnings & Growth
Current Price
$87.27
EPS (TTM)
$1.79
Forward P/E
25.9
Profit Margin
17.4%
Cash & Balance Sheet
Free Cash Flow
902.1M
EBITDA
1.9B
Book Value
$17.90
Total Debt
702.9M
What Do Analysts Say About EW?
Low
$84.00
Average
$98.58
High
$110.00
Upside
+13.0%
EW Fair Value FAQ
What is the fair value of EW?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), EW's estimated fair value is $50.42. The stock is currently trading at $87.27, which makes it overvalued by our analysis.
How is EW's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is EW overvalued or undervalued?
Based on our analysis, EW is overvalued. The current price of $87.27 is 42.2% above our estimated fair value of $50.42.
What do Wall Street analysts say about EW?
26 analysts cover Edwards Lifesciences with a consensus rating of "Buy." The average price target is $98.58, ranging from $84.00 to $110.00. This implies 13.0% upside from the current price.